You are here: Industry Insights > Clinical Trial

News List

PD-1 Inhibitor Combined with ADC, the Strong Cooperation of Innovent and Remegen Far-away from the Crowd/PharmaSources
July 25, 2023
Recently, Innovent and Remegen will carry out a clinical research cooperation on the combination of Sintilimab Injection, a PD-1 inhibitor, with RC88, a novel antibody-drug conjugate targeting MSLN, and RC108, a novel ADC targeting c-MET, res.
InnoCare and Keymed Jointly Announce First Subject Dosed in Clinical Trial of CCR8 Monoclonal Antibody ICP-B05 PharmaSources
February 24, 2023
InnoCare Pharma and Keymed Biosciences that the first subject has been dosed in clinical trial of ICP-B05.
New Progress of Key Chinese COVID-19 Drugs under Research PharmaSources/Xiaoyaowan
October 28, 2021
With the wide spread of Delta mutant worldwide, the COVID-19 infection situation is worrisome. In addition to vaccination for prevention, drug therapy can alleviate the disease deterioration...
Pharmaceutical News of the Week (July. 6th-July. 10th) | PharmaSources.com - Updates on R&D PharmaSources/Caicai
July 21, 2020
With the second week of July coming to a close, let’s review the hot events of the pharmaceutical industry this week. The news involved 6 sections: approval, R&D, policies, transactions, listing and miscellany that happened during July 6-10.
Cell Therapy Expected to Treat Solid Tumors in the Future as a CAR-T cell Therapy Clinical Trial for Treating Gastric and Pancreatic Cancers was Accepted PharmaSources/Xiaobin
June 17, 2020
CAR-T cells can be easily led to cancer cells by relying on this target, to wipe out cancer. However, there is no such apparent target that only exists in tumor cells instead of normal cells in solid tumors.
SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with Cetuximab PharmaSources
January 19, 2023
SOTIO Biotech announced today that the first patient was dosed in its Phase 2 AURELIO-05 combination trial of nanrilkefusp alfa (previously known as SOT101), an IL-15 superagonist, and cetuximab in patients with colorectal cancer.
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations PharmaSources.com
January 05, 2023
HighTide Therapeutics announced the closing of a $107 million Series C/C+ financing led by the TCM Healthcare Fund of Guangdong, managed by China Development Bank Capital. Other investors included Yuexiu Fund and Yuthai Fund.
Thermo Fisher Scientific Partners with Medidata Acorn AI to Optimize Clinical Research Site Selection and Speed Patient Enrollment in Clinical Trials AmericanPharmaceuticalReview
February 10, 2022
Thermo Fisher Scientific has announced a multiyear partnership with Medidata Acorn AI, a Dassault Systèmes company. Through this partnership, the PPD clinical research business of Thermo Fisher has collaborated with Medidata...
Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease at 18th Annual WORLDSymposium FirstWordPharma
February 10, 2022
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases...
HanAll Biopharma Reports Full-Year 2021 Results and Provides Business Update prnasia
January 21, 2022
HanAll Biopharma (KRX: 009420.KS) announced today that it achieved 101.6 billion won in sales in 2021, a 15% increase from the previous year. It had 10.1 billion won in operating profit, a 70% increase year-on-year...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page